## Alex P Hunyor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6311204/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prepapillary vascular loop-a new classification. Eye, 2021, 35, 425-432.	2.1	6
2	SURGICAL MANAGEMENT OF TRAUMATIC MACULAR HOLE. Retina, 2020, 40, 290-298.	1.7	8
3	Macular Atrophy in Neovascular Age-Related Macular Degeneration. Ophthalmology, 2020, 127, 198-210.	5.2	51
4	Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration. JAMA Ophthalmology, 2019, 137, 372.	2.5	95
5	Early Pars Plana Vitrectomy for Treatment of Acute Infective Endophthalmitis. Asia-Pacific Journal of Ophthalmology, 2019, 8, 3-7.	2.5	40
6	Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen. Ophthalmology, 2019, 126, 723-734.	5.2	222
7	Projection of Long-Term Visual Acuity Outcomes Based on Initial Treatment Response in Neovascular Age-Related Macular Degeneration. Ophthalmology, 2019, 126, 64-74.	5.2	22
8	Outcomes of Eyes with Failed Primary Surgery for Idiopathic Macular Hole. Ophthalmology Retina, 2018, 2, 757-764.	2.4	21
9	Outcomes and Predictive Factors After Cataract Surgery in Patients With Neovascular Age-related Macular Degeneration. The Fight Retinal Blindness! Project. American Journal of Ophthalmology, 2018, 190, 50-57.	3.3	18
10	Topical antibiotics and intravitreal injections. Acta Ophthalmologica, 2018, 96, 435-441.	1.1	25
11	TWO YEAR OUTCOMES OF "TREAT AND EXTEND―INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2018, 38, 20-28.	1.7	83
12	PERIPAPILLARY PACHYCHOROID SYNDROME. Retina, 2018, 38, 1652-1667.	1.7	104
13	Dual roles of different redox forms of complement factor H in protecting against age related macular degeneration. Free Radical Biology and Medicine, 2018, 129, 237-246.	2.9	10
14	The Visual Outcomes of Macular Hole Surgery: A Registry-Based Study by the Australian and New Zealand Society of Retinal Specialists. Ophthalmology Retina, 2018, 2, 1143-1151.	2.4	22
15	Endophthalmitis After Intravitreal Injections in Patients With Self-reported Iodine Allergy. American Journal of Ophthalmology, 2017, 176, 256-257.	3.3	2
16	Nitration of tyrosines in complement factor H domains alters its immunological activity and mediates a pathogenic role in age related macular degeneration. Oncotarget, 2017, 8, 49016-49032.	1.8	16
17	Uveal Effusion. Journal of Glaucoma, 2016, 25, e329-e335.	1.6	15
18	Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. British Journal of Ophthalmology, 2016, 100, 1640-1645.	3.9	36

ALEX P HUNYOR

#	Article	IF	CITATIONS
19	Bullous Variant of Central Serous Chorioretinopathy. Ophthalmology, 2016, 123, 1541-1552.	5.2	56
20	Macular disease genetics and supplementation: the evidence for choosing wisely. Clinical and Experimental Ophthalmology, 2016, 44, 443-445.	2.6	0
21	The Effect of Postoperative Face-Down Positioning and of Long- versus Short-Acting Gas in Macular Hole Surgery. Ophthalmology, 2016, 123, 1129-1136.	5.2	68
22	Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review. International Journal of Retina and Vitreous, 2015, 1, 9.	1.9	65
23	Two-Year Outcomes of "Treat and Extend―Intravitreal Therapy for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 1212-1219.	5.2	148
24	Time to Initial Clinician-Reported Inactivation of Neovascular Age-Related Macular Degeneration Treated Primarily withÂRanibizumab. Ophthalmology, 2015, 122, 589-594.e1.	5.2	25
25	Long-Term Outcomes of Treatment ofÂNeovascular Age-Related MacularÂDegeneration. Ophthalmology, 2015, 122, 1837-1845.	5.2	206
26	Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data. British Journal of Ophthalmology, 2015, 99, 359-364.	3.9	18
27	Novel optical coherence tomography classification of torpedo maculopathy. Clinical and Experimental Ophthalmology, 2015, 43, 342-348.	2.6	59
28	23-Gauge Pars Plana Vitrectomy Versus Scleral Buckling Versus Combined Pars Plana Vitrectomy–Scleral Buckling for Medium-Complexity Retinal Detachment Repair. Asia-Pacific Journal of Ophthalmology, 2014, 3, 215-219.	2.5	12
29	Vitrectomy for diabetic macular edema: a systematic review and meta-analysis. Canadian Journal of Ophthalmology, 2014, 49, 188-195.	0.7	51
30	Comparison of Outcomes from a Phase 3 Study of Age-Related Macular Degeneration with a Matched, Observational Cohort. Ophthalmology, 2014, 121, 676-681.	5.2	41
31	Intravitreal Therapy in Bilateral Neovascular Age-Related MacularÂDegeneration. Ophthalmology, 2014, 121, 2073-2074.	5.2	13
32	EFFICIENT CAPTURE OF HIGH-QUALITY DATA ON OUTCOMES OF TREATMENT FOR MACULAR DISEASES. Retina, 2014, 34, 188-195.	1.7	104
33	Loss of Müller's Cells and Photoreceptors inÂMacular Telangiectasia TypeÂ2. Ophthalmology, 2013, 120, 2344-2352.	5.2	181
34	Twenty-Three-Gauge Pars Plana Vitrectomy With Inferior Retinectomy and Postoperative Perfluoro-n-Octane Retention for Retinal Detachment Repair. Asia-Pacific Journal of Ophthalmology, 2013, 2, 232-236.	2.5	0
35	To bleed or clot?. Clinical and Experimental Ophthalmology, 2013, 41, 315-317.	2.6	1
36	Pars Plana Vitrectomy Versus Combined Pars Plana Vitrectomy–Scleral Buckle for Secondary Repair of Retinal Detachment. Ophthalmic Surgery Lasers and Imaging Retina, 2013, 44, 374-379.	0.7	11

ALEX P HUNYOR

#	Article	IF	CITATIONS
37	Prospective Audit of Exudative Age-Related Macular Degeneration: 12-Month Outcomes in Treatment-NaÃ <sup>-</sup> ve Eyes. , 2013, 54, 5754.		34
38	Ultrastructural and clinical evidence of subretinal debris accumulation in type 2 macular telangiectasia. British Journal of Ophthalmology, 2012, 96, 1404-1409.	3.9	25
39	Endophthalmitis following intravitreal injection versus endophthalmitis following cataract surgery: clinical features, causative organisms and post-treatment outcomes. British Journal of Ophthalmology, 2012, 96, 1350.2-1350.	3.9	1
40	Endophthalmitis following intravitreal injection versus endophthalmitis following cataract surgery: clinical features, causative organisms and post-treatment outcomes. British Journal of Ophthalmology, 2012, 96, 862-866.	3.9	106
41	Does unintentional macular translocation after retinal detachment repair influence visual outcome?. Clinical and Experimental Ophthalmology, 2012, 40, 88-92.	2.6	29
42	Does unintentional macular translocation after retinal detachment repair influence visual outcome? Response. Clinical and Experimental Ophthalmology, 2012, 40, e127.	2.6	0
43	Trypan Blue to Assess Baerveldt Tube Patency After Repair of Its Obstruction. Journal of Glaucoma, 2011, 20, 571-572.	1.6	7
44	Syphilitic retinitis and uveitis in HIVâ€positive adults. Clinical and Experimental Ophthalmology, 2010, 38, 851-856.	2.6	47
45	Medical versus surgical management of retained lens fragments. Journal of Cataract and Refractive Surgery, 2009, 35, 2181.	1.5	5
46	Antiâ€VEGF therapy: riding the wave of change. Clinical and Experimental Ophthalmology, 2008, 36, 401-402.	2.6	0
47	Management of intraoperative tilting of the scleral-fixated intraocular lens in classical aniridia. British Journal of Ophthalmology, 2007, 91, 1247-1248.	3.9	2
48	Diagnostic and Therapeutic Challenges. Retina, 2007, 27, 1142-1147.	1.7	2
49	Pars Plana Vitrectomy for the Management of Retained Lens Material After Cataract Surgery. American Journal of Ophthalmology, 2007, 144, 364-370.	3.3	63
50	Photographic Essays. Unusual ocular metastasis from breast cancer. Clinical and Experimental Ophthalmology, 2006, 34, 74-76.	2.6	12
51	LUPUS CHOROIDOPATHY AND CHOROIDAL EFFUSIONS. Retina, 2002, 22, 643-647.	1.7	22
52	Ocular–central nervous system lymphoma mimicking posterior scleritis with exudative retinal detachment. Ophthalmology, 2000, 107, 1955-1959.	5.2	32